The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Keysight Technologies: "I think this company is doing incredibly well...Good stock." Merck: "Merck is too cheap...I think you buy the stock of Merck." Click here to download Jim Cramer's Guide to ...

Get local news you need to know to start your day with NBC 6's News Headlines newsletter. Merck: "Merck is too cheap...I think you buy the stock of Merck." Click here to download Jim Cramer's ...

Merck: "Merck is too cheap...I think you buy the stock of Merck." Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter.

"The Wheel of Time" season 3 is finally here this week. "The Rings of Power" season 2 has been and gone, meaning we're now looking ahead to Prime Video's other major fantasy saga. The show was ...

We’re still a few months out from the long-awaited return of Ginny & Georgia season 3, but good news keeps on coming. Today, we’ve managed to get our paws on the episode titles for the forthcoming ...

Shares of Merck & Co. Inc. MRK advanced 1.34% to $90.58 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.59% to 5,861. ...

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

However, this decline, in my opinion, is not critical for Merck's financial position, since sales of Januvia and Janumet account for only 3.1% of its total revenue. As always, Keytruda ...

Mer­ck said its “once-in-a-life­time” drug Keytru­da could be sub­ject to price re­duc­tions un­der the In­fla­tion Re­duc­tion Act, which would lead to a … ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...